Delayed-type hypersensitivity to fenofibrate

Journal of Investigational Allergology and Clinical Immunology

Volumn 22, Issue 4, 2012, Pages 304-305

  Pecora, V ^a   Nucera, E ^a   Aruanno, A ^a   Buonomo, A ^a   Schiavino, D ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Cell mediated drug allergy; Cross reactivity; Fibrates; Lipid lowering drugs

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BEZAFIBRATE; CORTICOSTEROID; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HISTAMINE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CASE REPORT; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG CROSS REACTIVITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERYTHEMA; EVENING DOSAGE; FEMALE; HUMAN; LONG TERM CARE; MACULOPAPULAR RASH; MORNING DOSAGE; MYALGIA; PATCH TEST; PRICK TEST; PROVOCATION TEST; RECOMMENDED DRUG DOSE; RISK REDUCTION; SIDE EFFECT; SKIN TEST; STRUCTURE ACTIVITY RELATION; URTICARIA;

AGED; BEZAFIBRATE; CROSS REACTIONS; DRUG HYPERSENSITIVITY; DYSLIPIDEMIAS; EMERGENCY MEDICAL SERVICES; FEMALE; FENOFIBRATE; HUMANS; HYPERSENSITIVITY, DELAYED; HYPOLIPIDEMIC AGENTS; SKIN TESTS;

EID: 84863321021     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Chyu Ky, Shah PK. Emerging therapies for atherosclerosis prevention and management. Cardiol Clin. 2011;29:123-35.
2. Moutzouri E, Kei A, Elisaf MS, Milionis HJ. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag. 2010;6:525-39.
3. Baker SK, Tarnopolsky MA. Statin-associated neuromyotoxicity. Timely Top Med Cardiovasc Dis. 2005;9:E26.
4. Guis S, Figarella-Branger D, Mattei JP, Nicoli F, Le Fur Y, Kozak-Ribbens G, Pellissier JF, Cozzone PJ, Amabile N, Bendahan D. In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum. 2006;55:551-7.
5. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J. 2004;147:956-65.
6. Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM, Selvaggi G, Weisbaum G, Tzakis AG, SchiffER. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy. 2008;28:1188-93.
7. Oms P, Assie N, Bruniguel F, Degryse AD, van Haverbeke G, Delhon A. Biochemical changes and morphological alterations of liver and kidney in hamsters after administration of the HMGcoenzyme A reductase inhibitor, simvastatin: prevention and reversibility by mevalonate. Pharmacol Toxicol. 1995;77:391-6.
8. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002;57:45-51.
9. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br J Dermatol. 2005;152:968-74.